BeiGene (NASDAQ:BGNE) Stock Rating Reaffirmed by JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their overweight rating on shares of BeiGene (NASDAQ:BGNEFree Report) in a research report sent to investors on Tuesday, Benzinga reports. JPMorgan Chase & Co. currently has a $185.00 price target on the stock.

BGNE has been the topic of a number of other research reports. StockNews.com upgraded shares of BeiGene from a sell rating to a hold rating in a report on Thursday, November 9th. Citigroup lowered their price objective on shares of BeiGene from $290.00 to $285.00 and set a buy rating for the company in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $261.40.

Read Our Latest Stock Report on BGNE

BeiGene Trading Down 3.3 %

Shares of BGNE opened at $142.88 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.16 and a quick ratio of 2.91. The firm has a 50 day simple moving average of $170.73 and a 200-day simple moving average of $183.94. BeiGene has a 1-year low of $132.95 and a 1-year high of $272.49. The stock has a market cap of $13.63 billion, a price-to-earnings ratio of -15.43 and a beta of 0.60.

BeiGene (NASDAQ:BGNEGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($3.38) by $5.39. The business had revenue of $781.30 million during the quarter, compared to analysts’ expectations of $596.75 million. BeiGene had a negative net margin of 43.53% and a negative return on equity of 23.83%. The company’s revenue was up 101.6% on a year-over-year basis. During the same period last year, the company posted ($5.39) EPS. Equities analysts forecast that BeiGene will post -7.05 EPS for the current fiscal year.

Institutional Trading of BeiGene

A number of institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in BeiGene in the 2nd quarter valued at approximately $40,000. PNC Financial Services Group Inc. raised its stake in shares of BeiGene by 26.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock valued at $54,000 after buying an additional 51 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of BeiGene by 166.4% in the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock valued at $60,000 after buying an additional 208 shares in the last quarter. Knights of Columbus Asset Advisors LLC raised its stake in shares of BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after buying an additional 76 shares in the last quarter. Finally, Exchange Traded Concepts LLC acquired a new position in shares of BeiGene in the 2nd quarter valued at $90,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeiGene Company Profile

(Get Free Report)

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Articles

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.